Braveheart Bio (NASDAQ:BRVE) Shares Gap Up – Here’s Why

Posted by Geri Gentry on Oct 22nd, 2026

Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) gapped up before the market opened on Thursday. The stock had previously closed at $20.27, but opened at $21.14. Braveheart Bio shares last traded at $21.2250, with a volume of 5,506 shares traded.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $40.00 price objective on shares of Braveheart Bio in a research report on Tuesday. Stifel Nicolaus started coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $45.00 target price on the stock. Zacks Research upgraded Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. TD Cowen began coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating for the company. Finally, Jefferies Financial Group assumed coverage on Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $48.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.25.

Check Out Our Latest Analysis on BRVE

Braveheart Bio Price Performance

The firm has a 50-day moving average of $24.31. The company has a market cap of $1.91 billion and a P/E ratio of -8.45.

Braveheart Bio (NASDAQ:BRVE – Get Free Report) last released its quarterly earnings results on Tuesday, September 8th. The company reported ($2.51) EPS for the quarter, missing the consensus estimate of ($0.25) by ($2.26). As a group, research analysts expect that Braveheart Bio, Inc. will post -1.48 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Bio Fund Iv L.P. Ah purchased 1,100,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the purchase, the insider directly owned 10,232,420 shares of the company’s stock, valued at $184,183,560. The trade was a 12.05% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Growth Opportunities F. Forbion purchased 1,680,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $30,240,000.00. Following the purchase, the insider directly owned 10,185,478 shares of the company’s stock, valued at $183,338,604. This trade represents a 19.75% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 8,751,942 shares of company stock worth $157,534,956.

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.